News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene International Sárl (CELG) Release: Study to Evaluate Dose and Schedule for Oral Epigenetic Therapy CC-486 in Lower-Risk MDS Presented at American Society of Hematology


12/10/2012 10:17:44 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data from a phase I study of oral, epigenetic therapy CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes (MDS) was presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, GA.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES